A multicenter phase 1/2 trial evaluated the acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine over 48 weeks in adolescents with HIV-1, focusing on patient-reported pain,...
A new analysis of US claims data examined preexposure prophylaxis prescribing patterns among commercially insured adolescents and young adults at increased risk for HIV, offering clinicians insights into...
New research weighed the benefits and harms of beginning antiretroviral therapy immediately in HIV positive individuals, rather than relying on CD4+ cell counts to determine when to begin treatment.
Researchers have created a molecule that may help to make HIV cells vulnerable to the immune system and could lead to the development of vaccines against the virus.
The CDC has issued new recommendations for healthcare providers following investigation of a large outbreak of HIV among injection drug users in southeastern Indiana.
